<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309723</url>
  </required_header>
  <id_info>
    <org_study_id>CEVR-2013-001</org_study_id>
    <nct_id>NCT02309723</nct_id>
  </id_info>
  <brief_title>Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.</brief_title>
  <official_title>A Survey of Clinicians to Assess the Influence of Beta-amyloid Imagining Information on the Diagnosis and Management of Hypothetical Patients With Cognitive Complaints</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <brief_summary>
    <textblock>
      When older patients develop cognitive problems - like memory loss - there may be any of
      several underlying causes, sometimes occurring in combination. Clinicians have a better
      chance of providing appropriate treatment if they understand what the cause of the problem
      is. A diagnostic tool can help the patient by helping the clinician to make a more accurate
      diagnosis. This study investigates whether a new diagnostic tool - beta amyloid imaging - may
      potentially improve medical practice. The tool can potentially improve practice only if it
      can influence clinical judgment. This study investigates whether the provision of beta
      amyloid imaging information influences clinical judgment. The investigators will conduct a
      survey that presents clinicians with descriptions of hypothetical older patients with
      cognitive complaints. Some of the respondents also receive beta amyloid imaging information.
      The investigators will test the investigators hypothesis that the information will affect
      diagnostic judgment and management recommendations by comparing the responses of clinicians
      who receive the beta amyloid information to the responses of clinicians who do not.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss</measure>
    <time_frame>Online Survey - completion during the estimated 2-3 month field period</time_frame>
    <description>Proportion of respondents who identify Alzheimer's Disease as the sole or a contributing factor that is responsible for the patient's cognitive complaint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Likelihood of Recommending a Medication Indicated for Alzheimer's Disease</measure>
    <time_frame>Online Survey - completion during the estimated 2-3 month field period</time_frame>
    <description>Proportion of respondents who recommend a medication indicated for the treatment of Alzheimer's Disease, including Acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, Typical antipsychotics - e.g., Chlorpromazine (Thorazine), Haloperidol (Haldol), Atypical antipsychotics - e.g., Clozapine (Clozaril), Risperidone (Risperdal), Antidepressant - e.g., Citalopram (Celexa), Venlafaxine (Effexor), Antianxiety agent - e.g. Benzodiazepines, Buspirone (Buspar).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures</measure>
    <time_frame>Online Survey - completion during the estimated 2-3 month field period</time_frame>
    <description>Proportion of respondents who recommend that the patient's spouse take actions that would be appropriate if the patient has Alzheimer's disease, including: (1) discussion of advance care planning, (2) monitoring of patient's finances, (3) assessment of how compatible the patient's job is with his conditions, (4) the initiation of precautions to ensure the patient is properly taking his medications to manage hypertension and hyperlipidemia.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">315</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Positive beta amyloid findings</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beta amyloid imaging results indicated a positive finding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative beta amyloid findings</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beta amyloid imaging results indicated a negative finding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No beta amyloid information</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Beta amyloid imaging</intervention_name>
    <arm_group_label>Positive beta amyloid findings</arm_group_label>
    <arm_group_label>Negative beta amyloid findings</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Practicing clinicians describing their training and practice as any of the following:
             neurologist, geriatrician, psychiatrist.

          -  Included respondents must also attest that they are a physician who is experienced in
             the assessment and diagnosis of dementia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua T. Cohen, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter J Neumann, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <results_first_submitted>September 26, 2016</results_first_submitted>
  <results_first_submitted_qc>February 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Neuroimaging</keyword>
  <keyword>Diagnostic Tool</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Positive Beta Amyloid Findings</title>
          <description>Beta amyloid imaging results indicated a positive finding.
Beta amyloid imaging</description>
        </group>
        <group group_id="P2">
          <title>Negative Beta Amyloid Findings</title>
          <description>Beta amyloid imaging results indicated a negative finding.
Beta amyloid imaging</description>
        </group>
        <group group_id="P3">
          <title>No Beta Amyloid Information</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="105"/>
                <participants group_id="P3" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>number of clinicians responded to the email</population>
      <group_list>
        <group group_id="B1">
          <title>Positive Beta Amyloid Findings</title>
          <description>Survey respondents presented scenario in which beta amyloid imaging results indicated a positive finding.</description>
        </group>
        <group group_id="B2">
          <title>Negative Beta Amyloid Findings</title>
          <description>Survey respondents presented scenario in which beta amyloid imaging results indicated a negative finding.</description>
        </group>
        <group group_id="B3">
          <title>No Beta Amyloid Information</title>
          <description>Survey respondents presented scenario with no beta amyloid information.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="104"/>
            <count group_id="B4" value="315"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline characteristics are reported by subject.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="8.8"/>
                    <measurement group_id="B2" value="51.5" spread="7.8"/>
                    <measurement group_id="B3" value="52.7" spread="8.0"/>
                    <measurement group_id="B4" value="51.8" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta Amyloid imaging findings</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss</title>
        <description>Proportion of respondents who identify Alzheimer's Disease as the sole or a contributing factor that is responsible for the patient's cognitive complaint.</description>
        <time_frame>Online Survey - completion during the estimated 2-3 month field period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Positive Beta Amyloid Findings</title>
            <description>Beta amyloid imaging results indicated a positive finding.
Beta amyloid imaging</description>
          </group>
          <group group_id="O2">
            <title>Negative Beta Amyloid Findings</title>
            <description>Beta amyloid imaging results indicated a negative finding.
Beta amyloid imaging</description>
          </group>
          <group group_id="O3">
            <title>No Beta Amyloid Information</title>
          </group>
        </group_list>
        <measure>
          <title>Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss</title>
          <description>Proportion of respondents who identify Alzheimer's Disease as the sole or a contributing factor that is responsible for the patient's cognitive complaint.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diagnosis confidence: not at all confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diagnosis confidence: somewhat confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diagnosis confidence: confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diagnosis confidence: very confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diagnosis confidence: extremely confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Likelihood of Recommending a Medication Indicated for Alzheimer's Disease</title>
        <description>Proportion of respondents who recommend a medication indicated for the treatment of Alzheimer's Disease, including Acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, Typical antipsychotics – e.g., Chlorpromazine (Thorazine), Haloperidol (Haldol), Atypical antipsychotics – e.g., Clozapine (Clozaril), Risperidone (Risperdal), Antidepressant – e.g., Citalopram (Celexa), Venlafaxine (Effexor), Antianxiety agent – e.g. Benzodiazepines, Buspirone (Buspar).</description>
        <time_frame>Online Survey - completion during the estimated 2-3 month field period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Positive Beta Amyloid Findings</title>
            <description>Beta amyloid imaging results indicated a positive finding.
Beta amyloid imaging</description>
          </group>
          <group group_id="O2">
            <title>Negative Beta Amyloid Findings</title>
            <description>Beta amyloid imaging results indicated a negative finding.
Beta amyloid imaging</description>
          </group>
          <group group_id="O3">
            <title>No Beta Amyloid Information</title>
          </group>
        </group_list>
        <measure>
          <title>Likelihood of Recommending a Medication Indicated for Alzheimer's Disease</title>
          <description>Proportion of respondents who recommend a medication indicated for the treatment of Alzheimer's Disease, including Acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, Typical antipsychotics – e.g., Chlorpromazine (Thorazine), Haloperidol (Haldol), Atypical antipsychotics – e.g., Clozapine (Clozaril), Risperidone (Risperdal), Antidepressant – e.g., Citalopram (Celexa), Venlafaxine (Effexor), Antianxiety agent – e.g. Benzodiazepines, Buspirone (Buspar).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures</title>
        <description>Proportion of respondents who recommend that the patient's spouse take actions that would be appropriate if the patient has Alzheimer's disease, including: (1) discussion of advance care planning, (2) monitoring of patient's finances, (3) assessment of how compatible the patient's job is with his conditions, (4) the initiation of precautions to ensure the patient is properly taking his medications to manage hypertension and hyperlipidemia.</description>
        <time_frame>Online Survey - completion during the estimated 2-3 month field period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Positive Beta Amyloid Findings</title>
            <description>Beta amyloid imaging results indicated a positive finding.
Beta amyloid imaging</description>
          </group>
          <group group_id="O2">
            <title>Negative Beta Amyloid Findings</title>
            <description>Beta amyloid imaging results indicated a negative finding.
Beta amyloid imaging</description>
          </group>
          <group group_id="O3">
            <title>No Beta Amyloid Information</title>
          </group>
        </group_list>
        <measure>
          <title>Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures</title>
          <description>Proportion of respondents who recommend that the patient's spouse take actions that would be appropriate if the patient has Alzheimer's disease, including: (1) discussion of advance care planning, (2) monitoring of patient's finances, (3) assessment of how compatible the patient's job is with his conditions, (4) the initiation of precautions to ensure the patient is properly taking his medications to manage hypertension and hyperlipidemia.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Positive Beta Amyloid Findings</title>
          <description>Beta amyloid imaging results indicated a positive finding.
Beta amyloid imaging</description>
        </group>
        <group group_id="E2">
          <title>Negative Beta Amyloid Findings</title>
          <description>Beta amyloid imaging results indicated a negative finding.
Beta amyloid imaging</description>
        </group>
        <group group_id="E3">
          <title>No Beta Amyloid Information</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Yue Zhong, Project Director of Center for the Evaluation of Value and Risk in Health</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>6176361424</phone>
      <email>yzhong@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

